Cohance Lifesciences Limited has informed the Exchange about Transcript
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences (formerly Suven Pharmaceuticals) shared its first earnings call under the new identity post-merger. FY25 revenue grew 9% year-on-year to a $335 million integrated platform with EBITDA margins of 34%. Q4 FY25 revenue grew 20% YoY, with adjusted EBITDA margins at 31.3%. The Pharma CDMO segment grew 18% YoY, the Phase-3 pipeline expanded to 9 active molecules (from 2 in Sept '23), and commercial molecules rose to 16 (from 10). For FY26, management guided to double-digit revenue growth ('certainly in the teens') with all three business units (Pharma CDMO, Specialty Chemicals, API+) firing, but EBITDA margins are expected to dip to the low 30s due to acquisition integration, inventory de-stocking, and investments made ahead of scale. The company reiterated its $1 billion revenue target by 2030. CAPEX of Rs. 314 crore in FY25 is expected to rise to around Rs. 350 crore in FY26, and the balance sheet remains net cash with Rs. 2.9 billion in cash.
FY26 EBITDA margin dip to low 30s from 34% in FY25 may weigh on near-term sentiment, but management framed it as temporary, with mid-30s targeted at scale. Double-digit growth guidance across all three segments and ongoing M&A optionality (net cash, programmatic acquisition approach) support the long-term $1 billion by 2030 thesis.